22 September 2014


(“Sareum” or the “Company”)

CHK1 Patent Update

Sareum (AIM: SAR), the specialist cancer drug discovery and development business, is pleased to announce that the European Office has issued notification of a grant of a patent for one of the inventions associated with the CHK1 cancer programme.

The patent* describes compounds that inhibit CHK1 kinase enzyme function and their potential to treat cancer, when administered alone or in combination with chemotherapy or radiotherapy. The CHK1 cancer programme is a co-development collaboration between the Cancer Research Technology Pioneer Fund, Sareum and BACIT Ltd.

This patent, which has also been granted in the USA, is part of a wide intellectual property estate which, if granted in its current form, would provide broad geographical protection for the CHK1 programme.

* Patent No. EP2288601

Sareum’s CEO, Dr Tim Mitchell, commented: “The intellectual property that underpins the CHK1 cancer programme continues to develop, protecting the asset and enhancing its commercial value”.

Sareum Holdings plc


Tim Mitchell

01223 497 700

Sanlam Securities UK Limited (Nomad)

Simon Clements / James Thomas

020 7628 2200

Hybridan LLP (Broker)


Claire Noyce / William Lynne

0203 713 4581 / 4582

The Communications Portfolio (Media enquiries)


Ariane Comstive


020 7536 2028

Notes for editors:

About Sareum Holdings plc

Sareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

Sareum operates an outsourced research model, working with collaborators (SRI International, the CRT Pioneer Fund and Hebei Medical University Biomedical Engineering Center) and a world-wide network of research providers.  Its research pipeline includes two programmes undergoing pre-clinical IND-enabling studies.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3, Aurora+ALK, VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL® can also generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the symbol SAR. For further information, please visit www.sareum.co.uk

About CHK1 Kinase

CHK1 is important in controlling the way many cancer cells respond to DNA damage, which may be a consequence of the cancer itself, or intentionally caused by chemotherapy or radiotherapy. Inhibition of CHK1 affects the ability of the cell to repair this damage and can therefore potentiate the effect of certain chemotherapeutic drugs.  The candidate CHK1 inhibitor to be developed could potentially treat a range of cancers including pancreatic, bowel and non-small cell lung cancer (NSCLC) in combination with DNA-damaging chemotherapy drugs and/or radiotherapy. The inhibitor could also potentially treat certain neuroblastoma, lymphoma and acute myeloid leukaemia (AML) types when dosed alone.